AKT1 and pachyonychia congenita: In another clinical trial, a combination of ipatasertib (inhibitor of all three isoforms of protein kinase AKT, which blocks the PI3K/AKT signaling pathway—a key driver of cancer cell growth and proliferation in PC), atezolizumab (anti-PD-L1 monoclonal antibodies)—a checkpoint inhibitor on MDSCs (86), and docetaxel (NCT03673787) will be tested in patients with mCRPC.